COMPUGEN LTD·4

Apr 15, 4:10 PM ET

Ophir Eran 4

Research Summary

AI-generated summary

Updated

Compugen (CGEN) CEO Ophir Eran Exercises Options, Sells Shares

What Happened Ophir Eran, President & CEO and a director of Compugen Ltd. (CGEN), exercised stock derivatives and sold shares on April 14, 2026. The filing reports he acquired 5,000 shares by exercising at $0.83 per share (cost $4,146) and sold 5,000 shares in the open market at a weighted average price of $2.90 per share for proceeds of $14,521. The same filing also shows a separate exercise/conversion of 5,000 derivative shares reported as disposed at $0.00.

Key Details

  • Transaction date: 2026-04-14 (reported on Form 4 filed 2026-04-15).
  • Exercises/acquisitions: 5,000 shares @ $0.83 (total $4,146).
  • Sale: 5,000 shares sold in open market @ weighted avg $2.90 (total $14,521). Footnote: sale prices ranged $2.90–$2.91; detailed split available on request.
  • Additional derivative entry: 5,000 shares reported as exercised/converted and disposed @ $0.00 (listed as derivative).
  • Shares owned after transaction: Not specified in the provided filing details.
  • Footnotes of note:
    • F1: Sale was made under a Rule 10b5-1 trading plan adopted Dec 26, 2025.
    • F3: The option’s vesting schedule: 25% vested Dec 31, 2023; remainder vests in 12 equal quarterly installments subject to continued service.
  • Timeliness: Filing appears timely (transaction 4/14, Form 4 filed 4/15).

Context The sequence shows an option/derivative exercise followed by an immediate open-market sale of the exercised shares on the same day, which effectively monetizes vested option value. The presence of a Rule 10b5-1 plan indicates the sale was executed under a pre-established plan. The $0.00 derivative disposal is listed in the filing but not explained there; Form 4s sometimes show zero-dollar conversions/settlements for certain awards or transfers — the filing footnotes or the company’s disclosure may provide further detail.